BARDA seeks partners to develop host-directed therapeutic solutions to improve long-term recovery from acute respiratory distress

About Image

Now accepting submissions for therapeutic approaches with the potential to improve long-term patient outcomes.

BARDA's Division of Research, Innovation, and Ventures (DRIVe) opened a new area of interest (AOI) under the Easy Broad Agency Announcement (EZ-BAA) solicitation to evaluate new intervention strategies for acute respiratory distress with the goal of improving long-term patient recovery months after receiving critical care. This topic will expand DRIVe’s host-directed therapeutics program and bring forth solutions for patients to prevent consequences from severe illness.

Lung injury or respiratory distress caused by infectious agents, or due to physical injury during a chemical, biological, radiological, or nuclear (CBRN) incident, can lead to hospitalizations and severe outcomes such as sepsis and acute respiratory distress syndrome (ARDS). These conditions can have long-term health consequences that linger beyond the initial discharge from the hospital. Interventional therapies that can be administered in the hospital are needed to improve long-term patient outcomes, including mental, physical and social impairments, risk of health deterioration, or even to prevent mortality.

In this new EZ-BAA AOI #12, “Mitigating Long-term Effects (MILE) of Respiratory Distress”, BARDA DRIVe is seeking host-directed therapeutic candidates to expand our threat-agnostic, host therapeutics portfolio. Host-directed therapeutics are products that strengthen a person’s internal defense mechanisms against disease by countering dysregulation of the host response, helping to reduce organ damage, morbidity and mortality.

This program seeks to identify and support candidates that are already being evaluated to treat acute lung injury and can expand the clinical study design or analysis to assess impact to long-term (>3 months) consequences resulting from the initial emergency. This AOI focuses on therapeutic candidates, including novel clinical management approaches or interventions. The goal is to restore or maintain health characteristics, reduce hospital readmission and improve patient outcomes. Ultimately these medical countermeasures could aid in the current COVID-19 pandemic or future health security emergencies involving respiratory injury.

Abstracts may be submitted until 5:00PM ET on April 30, 2022. For additional information, see solicitation AOI #12: Mitigating Long-term Effects (MILE) of respiratory distress (PDF - 286KB) in the Special Instructions 015 Issuance of the EZ-BAA (BAA-20-100-SOL-0002), and visit

About Image


BARDA's Division of Research, Innovation, and Ventures (DRIVe) established the Easy Broad Agency Announcement (EZ-BAA) to streamline the application process for the review of transformative products and technologies to protect the U.S. from health security threats. Since its inception in 2018, BARDA DRIVe's EZ-BAA solicitation has received hundreds of abstract submissions annually, with awards made in as few as 30 days. The EZ-BAA has helped transform the solicitation process and provides innovators, entrepreneurs, and organizations with a simplified and rapid mechanism to propose ideas to the U.S. government. The application process is both business-friendly and easy to follow.

Last Updated: December 17, 2021